Keytruda Pembrolizumab 100mg/4ml

Keytruda Pembrolizumab 100mg/4mL contains pembrolizumab, an immune checkpoint inhibitor that targets the PD-1 pathway. By blocking this pathway, it helps T-cells recognize and attack certain cancer cells.

Key Information

• Active Ingredient: Pembrolizumab
• Strength: 100mg/4mL
• Form: Concentrate for intravenous infusion
• Administration: Administered by a qualified healthcare professional in a hospital or clinic setting.
• Uses: Used for various cancers, including melanoma, non-small cell lung cancer, head and neck cancer, classical Hodgkin lymphoma, urothelial cancer, kidney cancer, triple-negative breast cancer and certain colorectal, gastric, esophageal, cervical and biliary tract cancers.
• Common Side Effects: Fatigue, nausea, diarrhea, rash and muscle pain may occur.
• Important: Serious immune-mediated reactions affecting organs such as the lungs, liver and colon can occur and require medical supervision.

Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice. Consult a qualified healthcare professional before starting or changing any medication.